Go To Health Media features health experts from around the world who bring evidence-based education from Western, alternative, and holistic practices. It is supported by our website and social media properties. We bring together the public (seeking relevant, reputable, and proven solutions to their healthcare needs) and healthcare providers and companies, trying to reach target audiences with quality information, services, and products. Follow-up connections with our experts are highlighted, so that we help our audiences achieve optimal health via reputable, up-to-date health information, services and products. Join us on our GoToHealth Podcast and our website at https://gotohealthmedia.com/video.
All content for Go To Health! is the property of Jonathan Marx, MBA and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Go To Health Media features health experts from around the world who bring evidence-based education from Western, alternative, and holistic practices. It is supported by our website and social media properties. We bring together the public (seeking relevant, reputable, and proven solutions to their healthcare needs) and healthcare providers and companies, trying to reach target audiences with quality information, services, and products. Follow-up connections with our experts are highlighted, so that we help our audiences achieve optimal health via reputable, up-to-date health information, services and products. Join us on our GoToHealth Podcast and our website at https://gotohealthmedia.com/video.
Migraineurs have long suffered with debilitating headaches, nausea, vomiting, halo effects, interrupted sleep, and missing daily activities, to remain in bed, in the dark, in isolation. Over the years, medicines have been developed that attempt to relieve migraine pain.
In 2018, the FDA approved Rinat Neuroscience’s Ajovy medication for use in adults, via a self-administered injection, which focused on preventing migraines in the first place. Migraine frequency was greatly reduced. In August 2025, Ajovy was approved for children from age 6 upwards. The results have been amazing, with kids now more fully enjoying daily activities with much less frequent migraine episodes.
Go To Health!
Go To Health Media features health experts from around the world who bring evidence-based education from Western, alternative, and holistic practices. It is supported by our website and social media properties. We bring together the public (seeking relevant, reputable, and proven solutions to their healthcare needs) and healthcare providers and companies, trying to reach target audiences with quality information, services, and products. Follow-up connections with our experts are highlighted, so that we help our audiences achieve optimal health via reputable, up-to-date health information, services and products. Join us on our GoToHealth Podcast and our website at https://gotohealthmedia.com/video.
